Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir and what is the scope of freedom to operate?
Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasabuvir sodium; ombitasvir, paritaprevir, ritonavir has six hundred and eighteen patent family members in fifty-four countries.
Summary for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
| International Patents: | 618 |
| US Patents: | 17 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
US Patents and Regulatory Information for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
Expired US Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Uruguay | 33667 | COMPUESTOS ANTIVIRALES | ⤷ Try a Trial |
| China | 103596941 | Anti-viral compounds | ⤷ Try a Trial |
| Japan | 5534533 | ⤷ Try a Trial | |
| Canada | 2938547 | COMPOSES ANTIVIRAUX (ANTI-VIRAL COMPOUNDS) | ⤷ Try a Trial |
| United Kingdom | 201400676 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for dasabuvir sodium; ombitasvir, paritaprevir, ritonavir
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340029 | C20150019 00156 | Estonia | ⤷ Try a Trial | PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015 |
| 2203431 | C02203431/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS |
| 2692346 | CR 2017 00049 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
| 2692346 | 132017000122534 | Italy | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(MAVIRET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1213, 20170728 |
| 2692346 | C02692346/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66472 22.09.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
